Community Drug / Alcohol Pathways. Rachael Sadegh DAAT Co-ordinator



Similar documents
Adult drug treatment plan 2007/08 Part 1 Section A: Strategic summary Section B: National targets Section C: Partnership performance expectations

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice

Sheffield Future Commissioning of Drug & Alcohol Community Treatment

Drug & Alcohol Services. in Tower Hamlets

Getting help for a drug problem A guide to treatment

Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP

Aim of presentation. Drug and Alcohol Services in Leicester. National Policy. Local Policy. Demographics. Aims and objectives of needs assessment

Hepatitis C. Screening, Diagnosis and Linkage to Care

HEPATITIS C. The Facts. Get Tested. Get Cured! Health

Principles for commissioning a substance misuse treatment system

(Health Scrutiny Sub-Committee 9 March 2009)

Croydon Drug and Alcohol Action Team

A handbook for people who have injected drugs

Patient Information Sheet

Specialist Alcohol & Drug Services in Lanarkshire

HIV -The Facts BLT 043

Hepatitis C Infections in Oregon September 2014

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

Offering Testing for Hepatitis B and C in Primary Care

The Recovery Pathway Service forms a key component of the Sunderland Integrated Substance Misuse Service, as illustrated below:

Alcohol and drugs prevention, treatment and recovery: why invest?

Preface. TTY: (888) or Hepatitis C Counseling and Testing, contact: 800-CDC-INFO ( )

AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS

Are you Hep C aware? awareness information support prevention To find out more visit

BASIC INFORMATION ABOUT HIV, HEPATITIS B and C, and TUBERCULOSIS Adapted from the CDC

Croydon Drug and Alcohol Services. Directory of drug and alcohol services available in Croydon

COMMUNICABLE DISEASE

Clinical Priorities for Alcohol and Drugs in Public Health

Consultation Paper on Commissioning Adults and Young People s Drug and Alcohol Services in Somerset

THE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas (972)

HIV/AIDS: General Information & Testing in the Emergency Department

Appendix 3 Exposure Incident Report Form

Adult drug treatment plan 2009/10. Part 1: Strategic summary, needs assessment and key priorities

english facts about hepatitis A, B and C

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

Profile of substance misuse in Wales Education, health and criminal justice data

1.How did I get Hepatitis C?

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

Trends in Drug Treatment

Take Action Against Hepatitis C For People in Recovery From Mental Illness or Addiction

Executive Member for Community Health and Wellbeing. Commissioned Alcohol Services and Current Performance Update

PLUS MAY EQUAL. Flu-Like Symptoms SORE THROAT, SWOLLEN GLANDS, FEVER, JOINT AND MUSCLE ACHES

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

Substance Misuse. See the Data Factsheets for more data and analysis:

POST-EXPOSURE PROPHYLAXIS (HIV, HEP B, HEP C)

Information about hepatitis C for patients and carers

CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA

Bsafe Blackpool Community Safety and Drugs Partnership. Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13

POST EXPOSURE PROPHYLAXI S

SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE

Directory for Substance Misuse Services in Caerphilly

Strengthening the HCV Continuum of Care

Rekindling House Dual Diagnosis Specialist

3/25/2014. April 3, Dennison MM, et al. Ann Intern Med. 2014;160:

Alcohol treatment Information for service users Page

Oldham Drug and Alcohol Treatment and Recovery System

Joint Commissioning Panel for Mental Health

Chapter 21. What Are HIV and AIDS?

SERVICE SPECIFICATION FOR THE PROVISION OF DELIVERY OF SERVICES FOR DRUG AND ALCOHOL TREATMENT AND RECOVERY. (Schedule 1 of the Agreement)

Viral Hepatitis Case Report

Treatments for drug misuse

HIV. Looking after your sexual health

GUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

Viral Hepatitis A, B, and C

WHAT YOU NEED TO KNOW ABOUT HEPATITIS C: A GUIDE FOR PEOPLE WITH HIV INFECTION

Rochdale Borough s Drug and Alcohol Treatment Services Service Directory

Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis

Medicare Drug Coverage Under Part A, Part B, and Part D

Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During

INFORMATION ABOUT HEPATITIS C

The story of drug treatment

SERVICE SPECIFICATION

MEWA HIV and Key Population programming

The Hepatitis B virus (HBV)

Oxfordshire Drug and Alcohol Treatment System

Invitation to Tender for Wandsworth Integrated Drug and Alcohol Treatment and Recovery Service. Reference: WAND-Q0157 Attachment 3: Specification

HOSC Report Integrated community drugs and alcohol service retendering options beyond April 2016

Protocol for Needle Stick Injuries Occurring to NY Medical College Students In Physicians Offices

Transcription:

Community Drug / Alcohol Pathways Rachael Sadegh DAAT Co-ordinator

Prevalence / Treatment in Tower Hamlets Estimated 3,561 Opiate / Crack users Estimated 773 Injecting drug Users Estimated 9,500 high risk drinkers Estimated 31,728 increasing risk drinkers Approx 1400 Opiate / Crack users in treatment annually Approx 650 drinkers in treatment annually

Figure 1: Trend in anti-hcv prevalence* among people who inject drugs in England: 2003-2013 (PHE) *During 2009 to 2011 there was a phased change in the sample collected in the survey from an oral fluid to dried blood spot (DBS). The sensitivity of the anti-hcv tests on these two sample types is different. The sensitivity of the oral fluid test for anti-hcv is approximately 92%, (28) that on DBS samples is close to 100%. Data presented here have been adjusted for the sensitivity of the oral fluid test.

HIV, hepatitis B & hepatitis C prevalence and injection site infections; NUTS Region London: 2003-2013 Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Sample type DBS DBS DBS DBS DBS Anti-HIV Prevalence 2.9% 3.9% 3.2% 4.0% 3.9% 3.8% 4.1% 4.3% 3.9% 3.7% 4.5% Number of samples anti-hiv positive 23 25 20 24 23 21 24 18 11 21 17 Total number of samples collected 801 645 628 593 594 546 591 418 280 573 377 Anti-HBc Prevalence 39% 40% 35% 45% 36% 28% 32% 33% 24% 28% 28% Proportion of samples anti-hbc positive 29% 30% 26% 34% 27% 21% 24% 28% 22% 24% 28% 28% Number of samples anti-hbc positive 234 194 166 201 160 114 140 84 26 68 159 104 Total number of samples collected 800 645 628 593 594 546 591 302 116 280 573 377 Anti-HCV Prevalence 60% 58% 62% 61% 65% 57% 59% 64% 48% 59% 59% Proportion of samples anti-hcv positive 55% 53% 57% 56% 60% 52% 54% 60% 61% 48% 59% 59% Number of samples anti-hcv positive 442 345 358 332 356 285 319 181 71 135 340 223 Total number of samples collected 800 645 628 593 594 546 591 302 116 280 573 377 Among those who had injected in preceding year Symptom of injection site infection 39% 44% 39% 43% 40% 37% 40% 38% Number reporting symptom 108 124 101 103 51 44 116 73 Total number answering question 274 281 258 238 127 120 293 194 * The sensitivity of the oral fluid test for anti-hcv is approximately 92%, and that for anti-hbc is approximately 75%. Anti-HIV Prevalence = (number of samples tested anti-hiv positive / total tested)x100. Anti-HBc Prevalence = [(number of oral fluids anti-hbc positive/0.75) + number of DBS anti-hbc positive] / (number of oral fluids + number of DBS)x100. Anti-HCV Prevalence = [(number of oral fluids anti-hcv positive/0.92) + number of DBS anti-hcv positive] / (number of oral fluids + number of DBS)x100. Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year. Data source: Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs

* The sensitivity of the oral fluid test for anti-hcv is approximately 92%, and that for anti-hbc is approximately 75%. Sharing of needles and syringes in preceding four weeks. Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey. Note: the definition used here is different from that used in previous data sets. Data source: Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs Hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region London: 2003-2013 Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Sample type DBS DBS DBS DBS DBS Hepatitis B vaccine uptake 53% 54% 62% 62% 66% 66% 69% 73% 70% 73% 75% Number reporting hepatitis B vaccine uptake 411 340 384 356 381 354 382 278 192 396 270 Total number answering question 781 630 617 573 579 533 554 382 274 541 362 HCV VCT Uptake 72% 73% 80% 85% 85% 82% 87% 89% 82% 89% 87% Number reporting a VCT for HCV 535 436 467 477 478 429 454 317 193 430 315 Total number answering question 742 597 585 561 562 526 522 358 236 481 364 Proportion aware of HCV infection 56% 60% 63% 75% 69% 65% 67% 69% 59% 65% 60% Number aware of their HCV infection 211 182 193 219 220 161 173 138 63 177 120 Total number answering question 379 302 307 293 319 249 260 201 107 271 201 HIV VCT uptake 72% 68% 75% 83% 80% 80% 82% 87% 76% 85% 88% Number reporting a VCT for HIV 539 410 443 468 456 420 434 321 195 425 317 Total number answering question 751 600 588 564 567 525 529 369 257 500 362 Among those who had injected in preceding four weeks Level of direct sharing 32% 26% 28% 23% 25% 19% 17% 25% 22% 15% 15% Number reporting direct sharing 148 88 87 61 69 44 41 38 21 36 22 Total number answering question 469 337 310 265 271 226 239 153 96 233 144 Level of sharing (direct & indirect) 55% 54% 50% 48% 53% 40% 34% 42% 31% 35% 36% Number reporting sharing 258 181 154 128 146 89 80 65 30 81 52 Total number answering question 465 338 310 266 277 225 237 155 96 231 144 Among those with two or more (anal or vaginal) sexual partners in preceding year Proportion always using a condom 26% 25% 26% 23% 30% 38% 34% 26% 18% 32% 33% Number always using a condom 54 46 41 29 39 51 35 20 12 41 24 Total number answering question 206 185 155 126 130 134 103 77 67 127 72

Proportion anti-hbc positive and HBV vaccine uptake (%) Trends in Hepatitis B prevalence and vaccine uptake # among PWID in EW&NI: 1990/98-2013 100% HBV HBV vaccine uptake HBV EW & NI 80% 60% 40% 20% 0% 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Survey Year Source: Survey data tables PHE, 2014 # Self reports, those receiving one or more vaccine doses.

Sentinel surveillance testing by service type Tower Hamlets Samples submitted to BLT March. 2002 February 2010 Total tests 29,267, total antibody +ve 1,277, estimated RNA +ve 950 type Number tested Number positive (%) GP 8477 220 (2%) GUM 1861 61 (3%) Occupational health 2810 8 A&E 750 46 (6%) Obs and Gynae 413 16 (3%) Specialist Drug 818 246 (30%) Renal medicine 2731 56 (2%) Specialist liver services General medical/surgical 344 18 (5%) 2572 295 (11%)

Prevention / Treatment for drug users Stop injecting OST/ detoxification / psychosocial interventions Needle exchange / safer injecting advice Low dead space needles Coloured equipment Foil Alongside OST Hepatitis B vaccination Frequent Hepatitis C screening user focussed HCV treatment

Prevention / treatment for drinkers Identification and Brief Advice Stop / reduce drinking Brief advice Psychosocial interventions Detoxification (community / residential) Anti-craving medications Nalmefene Address diet / parenteral vitamin supplementation LFTs / Ultrasound / CT

LB Tower Hamlets: Current Provision Referral sources GP Self Drug Probat ion CARAT CJS Oth er DIP Dellow Day Centre Somali SM Link Project RLH drug / alcohol nurses Treatment Health E1 Shared Care ISIS CDT SAU Community Alcohol Team Island Day Nafas Day and Abstinence Support network DIP Changes Nacro Interven tion and Link Harbour Centre Panel Other T4 Spot Purchase

Needle Exchange / Safer Injecting advice Referral sources GP Self Drug Probat ion CARAT CJS Oth er DIP Dellow Day Centre Somali SM Link Project RLH drug / alcohol nurses Treatment Health E1 Shared Care ISIS CDT SAU Community Alcohol Team + 4 pharmacies, Ambrose King Centre Island Day Nafas Day and Abstinence Support network DIP Changes Nacro Interven tion and Link Harbour Centre Panel Other T4 Spot Purchase

HBV Vaccination / HCV screening Referral sources GP Self Drug Probat ion CARAT CJS Other DIP Dellow Day Centre Somali SM Link Project RLH drug / alcohol nurses Treatment Health E1 Shared Care ISIS CDT SAU Community Alcohol Team Island Day Nafas Day and Abstinence Support network DIP Changes Nacro Interven tion and Link Harbour Centre Panel Other T4 Spot Purchase

BBV Headlines 200-300 individuals accessing service per quarter via treatment services 291 individuals registered with Chronic HCV infection Approx 40-50 new individuals tested for HCV each quarter Approx 10 new HCV cases each quarter 76-97% of treatment service caseload seen by BBV nurses HBV vaccination rates and HCV screening rates way above London average Award winning HCV treatment service

LB Tower Hamlets: Approved treatment system option Referral sources GP Self Probation CARAT CJS Other Other DIP Lot 1 Lead Referral RLH Drug and Alcohol service RLH Specialis t Midwife Treatment Lot 2 Lead Drugs and Alcohol Lot 3 Lead Support Health E1 Homeless Medical Centre Panel